SpringWorks Therapeutics price target lowered to $78 from $80 at Guggenheim
Guggenheim analyst Michael Schmidt lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $78 from $80 and ...
Guggenheim sees potential in Primoris, starts with a Buy
As previously reported, Guggenheim analyst Joseph Osha initiated coverage of Primoris (PRIM) with a Buy rating and $102 price target The firm ...
Time Out17d
All the art exhibits coming to NYC's Guggenheim Museum in 2025
With its stunning Frank Lloyd Wright design, the Guggenheim Museum is a piece of art in itself. Inside these rounded walls, you’ll find floor upon floor of artistic treasures. The modern and ...
Guggenheim Doubts Salesforce's Agentic AI Agentforce as an Effective Growth Factor
Agentforce was launched in September and already signed up 200 companies to deploy Agentforce as their smarter chatbot. Marc ...
Workday upgraded to Neutral at Guggenheim on reinvigorated growth
As previously reported, Guggenheim analyst John DiFucci upgraded Workday (WDAY) to Neutral from Sell with no price target While the firm still ...
Five pages from Marvel’s new Star Wars series shows Jedi badassery at its height
In these five unlettered pages from Star Wars: Jedi Knights #1, which Polygon can reveal courtesy of Marvel Comics, being ...
Long Island Press1d
Guggenheim Elementary guest speaker shares experiences in Africa
Third-grade students at Guggenheim Elementary School were given a unique cultural experience on Jan. 3 when guest presenter ...
Salesforce Stock’s AI Rally Is Over, Analyst Says. Why Now Could Be the Time to Sell.
Salesforce ended 2024 on a high note but fell on Monday after a Guggenheim analyst downgraded shares of the software company.